Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

ADHD Drugs Market Will Register a CAGR of Almost 6 Percent by 2023

By Reportlinker | June 13, 2019

The rising incidence rate of ADHD among children is one of the critical factors that will trigger the growth of the attention deficit hyperactivity disorder drugs market. The expansion of the patient pool with positive ADHD symptoms is fueling the demand for ADHD therapies. As per the CDC, in 2016. Approximately 9.4 percent of children aged 2-17 years were diagnosed with ADHD. Thus, a significant patient pool (aged between 12 and 17 years) rely on medications. This is expected to rise further with the increasing prevalence of the disease, thereby contributing to the growth of the market during the forecast period. Our analysts have predicted that the attention deficit hyperactivity disorder (ADHD) drugs market will register a CAGR of almost 6 percent by 2023.

Market Overview
Rising Government Support

The global ADHD drugs market is currently witnessing an increase in the number of government initiatives to promote the awareness of the disease and to fund drug development in the area of mental health therapeutics. Additionally, the Centers for Disease Control and Prevention (CDC) supports the National Resource Center (NRC) on ADHD, a program designed to help children and adults with ADHD. The NRC program provides information, resources, and advice to parents on how to help their children with ADHD. Thus, the rising government support to help people with ADHD is expected to drive the growth of the market during the forecast period.

Lack of Patient Compliance with ADHD Treatment
The pharmacological (medications) treatment with neuro-stimulant drugs is considered as the gold standard for the treatment of ADHD in children and adults. However, the multiple dosing regimens associated with neuro-stimulant drugs, such as methylphenidate and amphetamine, and the timely dosing and long duration of the treatment are leading to a decrease in the patient compliance with these drugs. This leads to a decline in the consumption of ADHD drugs, thereby impeding the growth of the market.

Competitive Landscape
The market appears to be highly fragmented. The presence of several companies, including Johnson & Johnson Services Inc. and NEOS Therapeutics Inc. makes the competitive environment quite intense. Factors such as the rising incidence rate of ADHD among children and the increasing government support will provide considerable growth opportunities to attention deficit hyperactivity disorder drugs manufactures. Amneal Pharmaceuticals Inc., Eli Lilly and Co., and Takeda Pharmaceutical Co. Ltd. are some of the major companies covered in this report.

Related Articles Read More >

Zantac
First Zantac trial slated for February 2023
Bausch Health
Bausch Health gets new chair
FDA logo
FDA prevented 317 drug shortages in 2021
Pharma 50
2022 Pharma 50: The 50 largest pharmaceutical companies

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards